A carregar...
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disruptin...
Na minha lista:
| Publicado no: | Leuk Lymphoma |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6237652/ https://ncbi.nlm.nih.gov/pubmed/29764250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2018.1457147 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|